Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.

Kondo, Shunsuke; Tajimi, Masaomi; Funai, Tomohiko; Inoue, Koichi; Asou, Hiroya; Ranka, Vinay Kumar; Wacheck, Volker; Doi, Toshihiko

Kondo, Shunsuke; Tajimi, Masaomi; Funai, Tomohiko; Inoue, Koichi; Asou, Hiroya; Ranka, Vinay Kumar; Wacheck, Volker; Doi, Toshihiko.

Afiliación

Kondo S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. shkondo@ncc.go.jp.
Tajimi M; Eli Lilly Japan K.K, Kobe, Japan.
Funai T; Eli Lilly Japan K.K, Kobe, Japan.
Inoue K; Eli Lilly Japan K.K, Kobe, Japan.
Asou H; Eli Lilly Japan K.K, Kobe, Japan.
Ranka VK; Eli Lilly Services India Private Limited, Bengaluru, India.
Wacheck V; Eli Lilly GmbH, Vienna, Austria.
Doi T; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.

Invest New Drugs ; 38(6): 1846, 2020 Dec.

Article en En | MEDLINE | ID: mdl-32894386

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Invest New Drugs Año: 2020 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google